

## Thrombozyten-Transfusionen: Aktuelle Aspekte und Kommentar zu Kapitel 2 „Thrombozytenkonzentrate“ der Querschnitts-Leitlinien zur Therapie mit Blutkomponenten und Plasmaderivaten der Bundesärztekammer 2008.

- 1) Bundesärztekammer. Querschnitts-Leitlinien zur Therapie mit Blutkomponenten und Plasmaderivaten. 2009
- 2) German Association of Physicians. Cross-Sectional Guidelines for Therapy with Blood Components and Plasma Derivatives. *Transf Med Hemother.* 2009;**36**:347-481.
- 3) Schrezenmeier, H. and Seifried, E. Buffy-coat-derived pooled platelet concentrates and apheresis platelet concentrates: which product type should be preferred? *Vox Sang.* 2010 epub ahead of print.
- 4) Burger, R. and Offergeld, R. Festlegung der Haltbarkeitsfrist von Thrombozytenkonzentraten mit dem Ziel der Reduktion lebensbedrohlicher septischer Transfusionsreaktionen durch bakterielle Kontamination. *Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz.* 2008;1884-1884.
- 5) Eder, A. F., Kennedy, J. M., Dy, B. A., Notari, E. P., Weiss, J. W., Fang, C. T. et al. Bacterial screening of apheresis platelets and the residual risk of septic transfusion reactions: the American Red Cross experience (2004-2006). *Transfusion.* 2007;**47**:1134-1142.
- 6) Arbeitskreis Blut. Ergänzung zum Votum 38 V38): Reduktion des Septikämierisikos bei der Anwendung von Thrombozytenkonzentraten . [http://www.rki.de/clin\\_179/nn\\_206138/DE/Content/Infekt/Blut/AK\\_Blut/Voten/Uebersicht/V\\_38/V38\\_manuskript.kript.templateId=raw.property=publicationFile.pdf/V38\\_manuskript.pdf](http://www.rki.de/clin_179/nn_206138/DE/Content/Infekt/Blut/AK_Blut/Voten/Uebersicht/V_38/V38_manuskript.kript.templateId=raw.property=publicationFile.pdf/V38_manuskript.pdf). 2008.
- 7) Sagmeister, M., Oec, L., and Gmur, J. A restrictive platelet transfusion policy allowing long-term support of outpatients with severe aplastic anemia. *Blood.* 1999;**93**:3124-3126.
- 8) Höchsmann, B, Seidel, H., Wiesneth, M., and Schrezenmeier, H. Is the Low Platelet Transfusion Trigger in the New Cross-Sectional German Guidelines of risk in outpatient setting? Prophylactic platelet transfusions in aplastic anemia. *Transf Med Hemother.* 2010;**36 (suppl. 1)**:38-38.
- 9) Swisher, K. K., Terrell, D. R., Vesely, S. K., Kremer Hovinga, J. A., Lammle, B., and George, J. N. Clinical outcomes after platelet transfusions in patients with thrombotic thrombocytopenic purpura. *Transfusion.* 2009;**49**:873-887.
- 10) Salama, A., Kiesewetter, H., Kalus, U., Movassaghi, K., and Meyer, O. Massive platelet transfusion is a rapidly effective emergency treatment in patients with refractory autoimmune thrombocytopenia. *Thromb Haemost.* 2008;**100**:762-765.
- 11) Spahr, J. E. and Rodgers, G. M. Treatment of immune-mediated thrombocytopenia purpura with concurrent intravenous immunoglobulin and platelet transfusion: a retrospective review of 40 patients. *Am J Hematol.* 2008;**83**:122-125.
- 12) Zumberg, M. S., del Rosario, M. L., Nejame, C. F., Pollock, B. H., Garzarella, L., Kao, K. J. et al. A prospective randomized trial of prophylactic platelet transfusion and bleeding incidence in hematopoietic stem cell transplant recipients: 10,000/L versus 20,000/microL trigger. *Biol Blood Marrow Transplant.* 2002;**8**:569-576.
- 13) Navarro, J. T., Hernandez, J. A., Ribera, J. M., Sancho, J. M., Oriol, A., Pujol, M. et al. Prophylactic platelet transfusion threshold during therapy for adult acute myeloid leukemia: 10,000/microL versus 20,000/microL. *Haematologica.* 1998;**83**:998-1000.
- 14) Wandt, H., Frank, M., Ehninger, G., Schneider, C., Brack, N., Daoud, A. et al. Safety and cost effectiveness of a 10 x 10<sup>9</sup>/L trigger for prophylactic platelet transfusions compared with the traditional 20 x 10<sup>9</sup>/L trigger: a prospective comparative trial in 105 patients with acute myeloid leukemia. *Blood.* 1998;**91**:3601-3606.
- 15) Gil-Fernandez, J. J., Alegre, A., Fernandez-Villalta, M. J., Pinilla, I., Gomez, Garcia, V, Martinez, C. et al. Clinical results of a stringent policy on prophylactic platelet transfusion: non-randomized comparative analysis in 190 bone marrow transplant patients from a single institution. *Bone Marrow Transplant.* 1996;**18**:931-935.
- 16) Heckman, K. D., Weiner, G. J., Davis, C. S., Strauss, R. G., Jones, M. P., and Burns, C. P. Randomized study of prophylactic platelet transfusion threshold during induction therapy for adult acute leukemia: 10,000/microL versus 20,000/microL. *J Clin Oncol.* 1997;**15**:1143-1149.

- 17) Rebulla, P., Finazzi, G., Marangoni, F., Avvisati, G., Gugliotta, L., Tognoni, G. et al. The threshold for prophylactic platelet transfusions in adults with acute myeloid leukemia. *Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto. N Engl J Med.* 1997;**337**:1870-1875.
- 18) Lawrence, J. B., Yomtovian, R. A., Hammons, T., Masarik, S. R., Chongkolwatana, V., Creger, R. J. et al. Lowering the prophylactic platelet transfusion threshold: a prospective analysis. *Leuk Lymphoma.* 2001;**41**:67-76.
- 19) Nurden, P. and Nurden, A. T. Congenital disorders associated with platelet dysfunctions. *Thromb Haemost.* 2008;**99**:253-263.
- 20) Coppola, A. and Di Minno G. Desmopressin in inherited disorders of platelet function. *Haemophilia.* 2008;**14 Suppl 1**:31-39.
- 21) Lozano, M. and Cid, J. The clinical implications of platelet transfusions associated with ABO or Rh(D) incompatibility. *Transfus Med Rev.* 2003;**17**:57-68.
- 22) Klumpp, T. R., Herman, J. H., Gaughan, J. P., Russo, R. R., Christman, R. A., Goldberg, S. L. et al. Clinical consequences of alterations in platelet transfusion dose: a prospective, randomized, double-blind trial. *Transfusion.* 1999;**39**:674-681.
- 23) Norol, F., Bierling, P., Roudot-Thoraval, F., Le Coeur, F. F., Rieux, C., Lavaux, A. et al. Platelet transfusion: a dose-response study. *Blood.* 1998;**92**:1448-1453.
- 24) Sensebe, L., Giraudeau, B., Bardiaux, L., Deconinck, E., Schmidt, A., Bidet, M. L. et al. The efficiency of transfusing high doses of platelets in hematologic patients with thrombocytopenia: results of a prospective, randomized, open, blinded end point (PROBE) study. *Blood.* 2005;**105**:862-864.
- 25) Heddle, N. M., Cook, R. J., Tinmouth, A., Kouroukis, C. T., Hervig, T., Klapper, E. et al. A randomized controlled trial comparing standard- and low-dose strategies for transfusion of platelets (SToP) to patients with thrombocytopenia. *Blood.* 2009;**113**:1564-1573.
- 26) Slichter, S. J. and McCullough, J. *Optimal Platelet Dose Strategy for Management of Thrombocytopenia (PLADO).* 2010
- 27) Wandt, H., Schaefer-Eckart, K., Frank, M., Birkmann, J., and Wilhelm, M. A therapeutic platelet transfusion strategy is safe and feasible in patients after autologous peripheral blood stem cell transplantation. *Bone Marrow Transplant.* 2006;**37**:387-392.
- 28) Wandt, H., Schaefer-Eckart, K., Wendelin, K., Thalheimer, M., Schwerdtfeger, R., Conradi, R. et al. A therapeutic platelet transfusion strategy without routine prophylactic transfusion is feasible and reduces platelet transfusion numbers significantly: Analysis of a randomized study after autologous stem cell transplantation. *Onkol.* 2009;**32 (suppl 4)**:87-87.
- 29) Wandt, H., Schaefer-Eckart, K., Pilz, B., Thalheimer, M., Ho, A. D., Schaich, M. et al. Experience with a Therapeutic Platelet Transfusion Strategy in Acute Myeloid Leukemia: Preliminary Results of a Randomized Multicenter Study After Enrolment of 175 Patients. *Blood.* 2010;**114**:20.
- 30) Heuft, H. G., Mende, W., and Blasczyk, R. A General Change of the Platelet Transfusion Policy from Apheresis Platelet Concentrates to Pooled Platelet Concentrates is Associated with a Sharp Increase in Donor Exposure and Infection Rates. *Transfus Med Hemother.* 2008;**35**:106-113.
- 31) Vamvakas, E. C. Relative safety of pooled whole blood-derived versus single-donor (apheresis) platelets in the United States: a systematic review of disparate risks. *Transfusion.* 2009.
- 32) Hellstern, P. and Hitzler, W. E. Platelet concentrates from whole blood donations: Time to say goodbye. *Transfus Med Hemother.* 2007;**34**:208-210.
- 33) Heddle, N. M., Arnold, D. M., Boye, D., Webert, K. E., Resz, I., and Dumont, L. J. Comparing the efficacy and safety of apheresis and whole blood-derived platelet transfusions: a systematic review. *Transfusion.* 2008;**48**:1447-1458.
- 34) Schrezenmeier, H., Walther-Wenke, G., Muller, T. H., Weinauer, F., Younis, A., Holland-Letz, T. et al. Bacterial contamination of platelet concentrates: results of a prospective multicenter study comparing pooled whole blood-derived platelets and apheresis platelets. *Transfusion.* 2007;**47**:644-652.
- 35) Hourfar, M. K., Jork, C., Schottstedt, V., Weber-Schehl, M., Brixner, V., Busch, M. P. et al. Experience of German Red Cross blood donor services with nucleic acid testing: results of screening more than 30 million blood donations for human immunodeficiency virus-1, hepatitis C virus, and hepatitis B virus. *Transfusion.* 2008;**48**:1558-1566.



- 36) Bolan, C. D., Greer, S. E., Cecco, S. A., Oblitas, J. M., Rehak, N. N., and Leitman, S. F. Comprehensive analysis of citrate effects during plateletpheresis in normal donors. *Transfusion*. 2001;**41**:1165-1171.
- 37) Bolan, C. D., Wesley, R. A., Yau, Y. Y., Cecco, S. A., Starling, J., Oblitas, J. M. et al. Randomized placebo-controlled study of oral calcium carbonate administration in plateletpheresis: I. Associations with donor symptoms. *Transfusion*. 2003;**43**:1403-1413.
- 38) Bolan, C. D., Cecco, S. A., Yau, Y. Y., Wesley, R. A., Oblitas, J. M., Rehak, N. N. et al. Randomized placebo-controlled study of oral calcium carbonate supplementation in plateletpheresis: II. Metabolic effects. *Transfusion*. 2003;**43**:1414-1422.
- 39) Dettke, M., Buchta, C., Bieglmayer, C., Kainberger, F., Macher, M., and Höcker, P. Short- and longterm effects of citrate on bone metabolism and bone mineral density in healthy plateletpheresis donors. *J Clin Apheresis*. 2003;**18**:87.
- 40) Henseler, O., Heiden, M., Haschberger, B., Hesse, J., and Seitz, R. [Report on notifications pursuant to Section 21 German Transfusion Act for 2007]. *Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz*. 2009;**52**:715-731.
- 41) Tinmouth, A., Tannock, I. F., Crump, M., Tomlinson, G., Brandwein, J., Minden, M. et al. Low-dose prophylactic platelet transfusions in recipients of an autologous peripheral blood progenitor cell transplant and patients with acute leukemia: a randomized controlled trial with a sequential Bayesian design. *Transfusion*. 2004;**44**:1711-1719.
- 42) Inverardi, D., Bocchio, C., Rossi, L., Mazzucco, L., De Paoli L., and Borzini, P. Clinical, immunologic, and technical factors affecting recovery of platelet count after platelet transfusion. *Haematologica*. 2002;**87**:893-894.

